HNCIG-4/DE-ESCALATE RESULTS PUBLISHED IN LANCET

cforest9
Dec 7, 2022
1 min read

January 5, 2019

On this phase III trial, patients with low-risk oropharyngeal cancer were assigned to receive standard cisplatin-based CRT or radiotherapy plus cetuximab. Compared with the standard of care regimen, cetuximab showed no toxicity benefit, and negatively impacted tumor control. https://pubmed.ncbi.nlm.nih.gov/30449623/

Recent Posts

See All

HNCIG-EPIC-OPC: PROGNOSTIC IMPLICATIONS OF P16 AND HPV DISCORDANCE: A MULTINATIONAL ANALYSIS, PUBLISHED IN LANCET ONCOLOGY

https://pubmed.ncbi.nlm.nih.gov/36796393/

HNCIG-ENDORSED RECOMMENDATIONS FOR POST-OP RT IN HNSCC IN PRESENCE OF FLAPS PUBLISHED BY GORTEC

https://pubmed.ncbi.nlm.nih.gov/33984351/

HNCIG CONSENSUS ON ENDPOINT DEFINITIONS IN CURATIVE-INTENT TRIALS FOR HNSCC PUBLISHED IN LANCET ONCOLOGY

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00067-6/fulltext